argenx to Present at BofA Securities 2025 Health Care Conference
argenx (ARGX), a global immunology company focused on severe autoimmune diseases, has announced its participation in the BofA Securities 2025 Health Care Conference. CEO Tim Van Hauwermeiren and other management team members will deliver a presentation on Tuesday, May 13, 2025, at 4:20 p.m. PT.
The presentation will be accessible through a live webcast on the Investors section of argenx's website at argenx.com/investors. A replay will remain available for approximately 30 days after the event.
argenx (ARGX), un'azienda globale di immunologia focalizzata su gravi malattie autoimmuni, ha annunciato la sua partecipazione alla BofA Securities 2025 Health Care Conference. Il CEO Tim Van Hauwermeiren e altri membri del team dirigenziale terranno una presentazione martedì 13 maggio 2025 alle 16:20 PT.
La presentazione sarà accessibile tramite una diretta web nella sezione Investitori del sito argenx all'indirizzo argenx.com/investors. Una registrazione sarà disponibile per circa 30 giorni dopo l'evento.
argenx (ARGX), una empresa global de inmunología enfocada en enfermedades autoinmunes graves, ha anunciado su participación en la BofA Securities 2025 Health Care Conference. El CEO Tim Van Hauwermeiren y otros miembros del equipo directivo ofrecerán una presentación el martes 13 de mayo de 2025 a las 4:20 p.m. PT.
La presentación estará disponible a través de una transmisión en vivo en la sección de Inversores del sitio web de argenx en argenx.com/investors. La repetición estará disponible aproximadamente durante 30 días después del evento.
argenx (ARGX), 중증 자가면역 질환에 집중하는 글로벌 면역학 기업이 BofA Securities 2025 Health Care Conference에 참여한다고 발표했습니다. CEO 팀 반 하우어메이렌과 경영진이 2025년 5월 13일 화요일 오후 4시 20분(태평양 시간)에 발표를 진행할 예정입니다.
발표는 argenx 웹사이트의 투자자 섹션(argenx.com/investors)에서 라이브 웹캐스트로 시청할 수 있으며, 행사 후 약 30일간 다시보기 서비스가 제공됩니다.
argenx (ARGX), une entreprise mondiale d'immunologie spécialisée dans les maladies auto-immunes sévères, a annoncé sa participation à la BofA Securities 2025 Health Care Conference. Le PDG Tim Van Hauwermeiren ainsi que d'autres membres de la direction présenteront une intervention le mardi 13 mai 2025 à 16h20 PT.
La présentation sera accessible via une webdiffusion en direct dans la section Investisseurs du site argenx à l'adresse argenx.com/investors. Une rediffusion sera disponible pendant environ 30 jours après l'événement.
argenx (ARGX), ein globales Immunologie-Unternehmen mit Schwerpunkt auf schweren Autoimmunerkrankungen, hat seine Teilnahme an der BofA Securities 2025 Health Care Conference angekündigt. CEO Tim Van Hauwermeiren und weitere Mitglieder des Management-Teams werden am Dienstag, den 13. Mai 2025, um 16:20 Uhr PT eine Präsentation halten.
Die Präsentation ist über einen Live-Webcast im Investor-Bereich der argenx-Website unter argenx.com/investors zugänglich. Eine Aufzeichnung wird etwa 30 Tage nach der Veranstaltung verfügbar sein.
- None.
- None.
May 6, 2025
Amsterdam, the Netherlands – argenx (Euronext & Nasdaq: ARGX), a global immunology company committed to improving the lives of people suffering from severe autoimmune diseases, today announced that Tim Van Hauwermeiren, Chief Executive Officer, and members of the management team will present at the BofA Securities 2025 Health Care Conference on Tuesday, May 13, 2025 at 4:20 p.m. PT.
A live webcast of the presentation may be accessed on the Investors section of the argenx website at argenx.com/investors. A replay of the webcast will be available on the argenx website for approximately 30 days following the presentation.
About argenx
argenx is a global immunology company committed to improving the lives of people suffering from severe autoimmune diseases. Partnering with leading academic researchers through its Immunology Innovation Program (IIP), argenx aims to translate immunology breakthroughs into a world-class portfolio of novel antibody-based medicines. argenx developed and is commercializing the first approved neonatal Fc receptor (FcRn) blocker and is evaluating its broad potential in multiple serious autoimmune diseases while advancing several earlier stage experimental medicines within its therapeutic franchises. For more information, visit www.argenx.com and follow us on LinkedIn, Instagram, Facebook, and YouTube.
Contacts
Media:
Ben Petok
bpetok@argenx.com
Investors:
Alexandra Roy
aroy@argenx.com
FAQ
When is ARGX presenting at the BofA Securities 2025 Health Care Conference?
Who will be presenting for ARGX at the BofA Securities healthcare conference?
How can investors access ARGX's BofA Securities conference presentation?
What does argenx (ARGX) company specialize in?
